Literature DB >> 12433709

p53 mutations in L3-loop zinc-binding domain, DNA-ploidy, and S phase fraction are independent prognostic indicators in colorectal cancer: a prospective study with a five-year follow-up.

Antonio Russo1, Manuela Migliavacca, Ines Zanna, Maria Rosaria Valerio, Mario Adelfio Latteri, Nello Grassi, Gianni Pantuso, Sergio Salerno, Gabriella Dardanoni, Ida Albanese, Mario La Farina, Rosa Maria Tomasino, Nicola Gebbia, Viviana Bazan.   

Abstract

p53 gene alterations are among the most common events observed in colorectal cancer,and are accompanied frequently by DNA aneuploidy and high proliferative activity. The prognostic significance of such mutations remains controversial. We prospectively evaluated the prognostic significance of p53 mutations, DNA-ploidy, and S phase fraction (SPF) in a consecutive series of 160 colorectal cancer patients (median follow-up 71 months). Tumor DNA was screened for p53 mutations by PCR/single-strand conformational polymorphism/sequencing. DNA-ploidy and SPF were assessed by DNA flow cytometry. p53 mutations were detected in 68 of 160 (42.5%) cases. In 56% (38 of 68) of these, p53 mutations were found in conserved areas of the gene and in 44% (30 of 68 cases) outside the conserved regions. Eighteen of the 68 cases (26%) had mutations in the L3 loop, 11 of 68 (16%) in the L1 loop-sheet-alpha helix motif, and 39 of 68 (58%) outside L3 and loop-sheet-alpha helix. Seventy-five percent of the cases (120 of 160) showed DNA aneuploidy, whereas 18% of these (22 of 120) were multiclonal. The major independent predictors for both disease relapse and death were advanced Dukes' stage, p53 mutations affecting L3 loop, DNA-aneuploid tumors, and high SPF (>18.5%). Our results show that mutations in L3 functional domain, more than any mutations, are important biological indicators to predict the outcome of patients indicating that these mutations have biological relevance in terms of colorectal cancer disease course.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12433709

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  5 in total

1.  Genetic dissimilarity between primary colorectal carcinomas and their lymph node metastases: ploidy, p53, bcl-2, and c-myc expression--a pilot study.

Authors:  Khaled Refaat Zalata; Mohamed Farouk Elshal; Abd AlRahman Mohammad Foda; Ashraf Shoma
Journal:  Tumour Biol       Date:  2015-04-04

2.  Colorectal cancer prognosis: is it all mutation, mutation, mutation?

Authors:  A B Hassan; C Paraskeva
Journal:  Gut       Date:  2005-09       Impact factor: 23.059

3.  Analytical validation of telomerase activity for cancer early detection: TRAP/PCR-CE and hTERT mRNA quantification assay for high-throughput screening of tumor cells.

Authors:  John P Jakupciak; Wendy Wang; Peter E Barker; Sudhir Srivastava; Donald H Atha
Journal:  J Mol Diagn       Date:  2004-08       Impact factor: 5.568

4.  Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803.

Authors:  Robert S Warren; Chloe E Atreya; Donna Niedzwiecki; Vivian K Weinberg; David B Donner; Robert J Mayer; Richard M Goldberg; Carolyn C Compton; Marlene B Zuraek; Cynthia Ye; Leonard B Saltz; Monica M Bertagnolli
Journal:  Clin Cancer Res       Date:  2013-08-27       Impact factor: 12.531

5.  Predictive and prognostic factors in colorectal cancer: a personalized approach.

Authors:  Myutan Kulendran; John F Stebbing; Christopher G Marks; Timothy A Rockall
Journal:  Cancers (Basel)       Date:  2011-03-29       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.